Bristol Myers Squibb Secures EU Approval for Opdivo-AVD Combo in Advanced Hodgkin Lymphoma

Event summary

  • Bristol Myers Squibb's Opdivo (nivolumab) in combination with AVD received EU approval for frontline treatment of advanced classical Hodgkin lymphoma in patients aged 12+.
  • The approval is based on Phase 3 SWOG 1826 trial data showing a 58% reduction in disease progression or death risk compared to standard therapy.
  • This marks the first immunotherapy-based regimen approved in the EU for newly diagnosed advanced classical Hodgkin lymphoma.
  • The approval is valid across all 27 EU member states plus Iceland, Liechtenstein, and Norway.

The big picture

This approval represents a significant strategic win for Bristol Myers Squibb in the competitive immuno-oncology space, particularly in hematologic malignancies. The company is expanding its Opdivo franchise beyond solid tumors into blood cancers, where treatment options have historically been more limited. This move aligns with broader industry trends toward earlier intervention with immunotherapy regimens to improve long-term remission rates in aggressive cancers.

What we're watching

Market Expansion
How quickly Bristol Myers Squibb can penetrate the EU market with this new indication, particularly in pediatric and adolescent populations.
Competitive Positioning
Whether this approval strengthens Opdivo's leadership in hematologic cancer treatments against competitors like Merck's Keytruda.
Regulatory Momentum
The pace at which similar approvals might be secured in other major markets, particularly the US where Opdivo-AVD was already approved in March 2026.

Related topics

Regulatory Approval